Genzyme occupies four facilities located in Boston and Cambridge, Mass., and Maidstone and Haverhill, U.K., with a total of 106,500 sq. ft.

Manufactures and sells approximately 20 diagnostic critical intermediates.

Constructs a facility on Binney Street in Cambridge, MA to produce medical grade hyaluronic acid (HA).

Opens an office in Tokyo to sell diagnostic enzymes, fine chemicals, and research biologicals.

Doubles pharmaceutical manufacturing capacity in Haverhill, U.K., partly funded by a government grant.

Senator Edward Kennedy officiates at opening of One Mountain Road, Framingham, MA and R&D facility.

Establishes Framingham, MA DNA laboratory.

Begins treating patients in Israel with Ceredase^® (alglucerase injection).

Opens Genzyme Biochemicals Research and Development Center in West Malling, Kent, U.K., to expand product research capabilities.

Begins construction on the state-of-the-art biopharmaceutical manufacturing plant in Allston, MA.

Announces plans to add 120,000 square feet to the Framingham facilities for R&D and manufacturing.

Begins to develop bulk HA manufacturing in Kent, U.K. (fermentation) and Haverhill, U.K. (purification).

Acquires Vivigen, Inc., Santa Fe, which becomes Genetics’ largest lab.

Opens office in Naarden, the Netherlands.

Genzyme Transgenics spins out to focus on development of transgenic recombinant proteins.

Acquires the leading peptide and lipid manufacturer Sygena, located in Liestal, Switzerland.

Purchases One and Five Mountain Road in Framingham for $26.9 million.

Acquires BioSurface Technologies, Cambridge, MA.

Completes bulk HA facilities in the U.K. and receives U.S. Food and Drug Administration (FDA) approval.

Upgrades the Liestal, Switzerland, pharmaceutical facility.

Acquires Genetrix and adds genetic testing labs in Tampa, FL and Yonkers, NY.

Opens an office in Ottawa, Ontario, Canada.

Establishes Genzyme Brazil.

Converts pharmaceutical plant in Haverhill, U.K. to a bulk Renagel^® manufacturing facility.

Expands Renagel production capacity in Haverhill, U.K., to 250 metric tons.

Genzyme Genetics doubles capacity in its Framingham DNA/molecular laboratory.

Major expansion of Liestal pharmaceutical plant after FDA grants approval.

Genzyme completes first 100 metric ton Renagel expansion at Haverhill, U.K.

Purchases a plant in Waterford, Ireland, to produce Renagel tablets and other products.

Acquires protein manufacturing facility in Geel, Belgium.

Ends year with 1,971,768 total square feet of facilities for manufacturing, R&D, and office space.

EMEA and FDA approve Renagel^® tableting at new Genzyme Plant in Ireland

Expands Allston manufacturing facility to include bioreactors for Fabrazyme^® and Myozyme^™.

Genzyme moves its headquarters to Genzyme Center, an innovative, environmentally-responsible, employee-focused building.